CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

UBS Adjusts BioMarin Pharmaceutical Price Target to $88 From $114, Maintains Buy Rating

Negative
AI Analysis

Summary

UBS lowered its price target on BioMarin Pharmaceutical to $88 from $114 while maintaining a Buy rating.

Outcome Details

UBS lowered price target to $88 from $114, maintained Buy rating

Importance:3/10
Sentiment:
-0.30
analyst_ratingprice_target_cut
Related Companies

Read the original article

Published by yahoo_finance on October 15, 2026 2:33 PM

Read Original